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AbsTrACT
Objectives adults with congenital heart disease 
(achD) are a growing group with end-stage heart 
failure. We aim to describe the outcomes of achD 
patients undergoing assessment for orthotopic heart 
transplant (Oht).
Methods case notes of consecutive achD patients 
(>16 years) assessed for Oht between 2000 and 2016 
at our centre were reviewed. Decision and outcome were 
reported as of 2017. Data were analysed in three groups: 
systemic left ventricle (lV), systemic right ventricle (rV) 
and single ventricle (sV).
results 196 patients were assessed (31.8 years, 
27% lV, 29% rV, 44% sV). 89 (45%) patients were 
listed for Oht and 67 (34%) were transplanted. 41 
(21%) were unsuitable or too high risk and 36 (18%) 
were too well for listing. conventional surgery was 
undertaken in 13 (7%) and ventricular assist device in 
17 (9%) with 7 (4%) bridged to candidacy. survival from 
assessment was 84.2% at 1 year and 69.7% at 5 years, 
with no difference between groups. Patients who were 
considered unsuitable for Oht (hr 11.199, p<0.001) 
and listed (hr 3.792, p=0.030) were more likely to die 
than those who were considered too well. assessments 
increased over the study period.
Conclusions the number of achD patients assessed 
for Oht is increasing. a third are transplanted with a 
small number receiving conventional surgery. those who 
are unsuitable have a poor prognosis.
bACkgrOund
Most infants with complex congenital heart disease 
now survive to adulthood.1 Mortality in these 
adults is higher than the general population, with 
heart failure the leading cause of death.2–5 Strat-
egies successful in acquired heart disease have 
uncertain survival benefit in the adult congenital 
heart disease (ACHD) heart failure population.6–8 
Orthotopic heart transplantation (OHT) is effective 
for selected patients,9 10 but donor organs are scarce 
and competing demands from those with other 
conditions contribute to waiting list mortality.11–13 
Despite better long-term outcomes from OHT, 
ACHD patients are at significant risk of peri-trans-
plant mortality9 10 and the role of OHT continues 
to be debated.
The present study reports outcomes of consec-
utive ACHD patients referred to us for OHT 
assessment.
MeThOds
study population
Consecutive ACHD patients (>16 years) assessed 
for OHT at our unit between 1 January 2000 and 1 
January 2016 for OHT were included. Case records 
were retrospectively reviewed. Clinical decision 
and outcomes were reported from 1 January 2017.
Patients were categorised into three groups:
 ► Left ventricle (LV): usual anatomic connections, 
two balanced ventricles with systemic LV
 ► Right ventricle (RV): ventriculo-arterial (±atri-
oventricular) discordance, two balanced ventri-
cles with systemic RV
 ► Single ventricle (SV): unbalanced ventricles 
with a physiological SV circulation.
Assessment and decision process
Newcastle on Tyne Hospitals NHS Foundation 
Trust is a specialist adult and paediatric congenital 
heart disease surgical centre and a national cardio-
thoracic transplant centre. The unit carries out the 
majority of the UK’s OHTs and ventricular assist 
devices (VAD) for ACHD patients.
Following referral, patients were admitted at 
least once for inpatient assessment. Decision to list 
for transplantation was made at a multidisciplinary 
team (MDT) meeting and categorised as follows:
 ► Unsuitable
 ► Conventional surgery/intervention preferred
 ► Too well and conventional surgery/interven-
tion not indicated
 ► Other (dual organ transplant, suitable but 
declined)
 ► Suitable and listed for OHT.
Unsuitable patients were those with an absolute 
contraindication or who were considered too high 
risk for OHT. Patients considered too well were 
those without significant functional limitation (New 
York Heart Association (NYHA) 1 or 2) and where 
there was felt to be no clear survival advantage from 
transplantation. Urgent listing status was based on 
the National Health Service Blood and Transplant 
(NHS BT) urgent allocation scheme introduced in 
1999.14 15 To assess change over time, results were 
compared over 4-year periods.
statistics
Normality of data was assessed using the Kolgo-
morov–Smirnov Test. All continuous variables were 
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not normally distributed (age, transpulmonary gradient (TPG), 
mean pulmonary artery pressure, pulmonary artery capillary 
wedge pressure, ventricular end diastolic pressure (EDP) and 
creatinine) and were expressed as median and interquartile range. 
Number of previous sternotomies was expressed as median and 
range. Groups were compared with the Kruskal–Wallis test and 
Dunn post-hoc test. Categorical data were expressed as abso-
lute number and percentage and compared using the column 
proportion method. Survival from assessment was assessed using 
Kaplan–Meier plots and predictors were assessed using the Cox 
proportional hazards model. Survival from listing and transplant 
were compared across diagnostic groups with the log rank test. 
If patients underwent more than one assessment, the first date 
of assessment was considered. Significance was implied with 
a two-tailed p value <0.05 and adjusted with the Bonferroni 
correction. Data were analysed in SPSS v.24.
ethics
The study was reviewed and non-requirement for approval by 
an NHS Research Ethics committee was confirmed by the chair 
of North East Tyne & Wear South Research Ethics committee.
resulTs
study population
Between 2000 and 2016, 196 patients (67% male, 31.8 years 
(IQR 23.4–41.1)) were assessed for OHT (tables 1 and 2, 
figure 1).
OuTCOMe fOllOwing AssessMenT fOr OhT
The outcome for each group of patients is described below and 
summarised in tables 3 and 4 and figure 1.
unsuitable for OhT
Forty-one of 196 (21%) were considered too high risk or inap-
propriate for OHT. Primary reasons were:
 ► Elevated TPG: Fourteen patients had a TPG too high for 
OHT. Five were LV patients (TPG 14–40 mm Hg), and three 
had aortic valve replacements as children with chroni-
cally elevated EDP due to longstanding patient–prothesis 
mismatch (two underwent conventional surgery). One was an 
SV patient who had previously undergone pulmonary artery 
banding. Eight were RV patients (TPG 16–56 mm Hg); four 
received VAD intended to reduce TPG (three died at 5 days, 
4 months and 7 months, and one remains on support at 17 
months). Six further RV patients had an initial TPG too high 
for OHT which was successfully reduced after VAD inser-
tion allowing listing.16
 ► Anatomical unsuitability: Three SV cases: diffusely hypo-
plastic pulmonary arteries (1), multiple areas of peripheral 
pulmonary artery stenosis (2).
 ► High panel reactive antibodies: Two cases, one underwent 
conventional surgery.
 ► Co-morbidity: Twelve patients (LV 4, SV 8). Six had multiple 
comorbidities (including concerns about future self-care, 
Table 1 Patient demographics and diagnoses at assessment for cardiac transplantation
All lV rV sV
P valuen=196 n=53 n=57 n=86
Male 131 (67%) 38 (72%) 42 (74%) 51 (59%) 0.137
Age (years) 31.8 (23.4–41.1) 37.2 (23.3–46.3) 34.2 (28.6–39.8) 28.3 (21.5–35.0) <0.001
diagnosis
Right heart pathology
(tetralogy of Fallot, pulmonary stenosis)
18 18 - -
Left heart pathology (aortic stenosis, Shone complex) 11 11 - -
Other (ventricular septal defect, venous drainage abnormalities) 7 7 - -
Ebstein anomaly 13 13* - -
Transposition of the great arteries 38
  Rastelli repair 3 - -
  Takedown Mustard/arterial switch 1 - -
  Mustard/Senning - 34 -
CCTGA 23 - -
  Unoperated 10
  Operated 13
Single ventricle 86
  Balanced (unoperated) - - 4
  Pulmonary artery band - - 3
  Shunt (various) - - 11
  Glenn - - 10†
  Fontan - -
   Atriopulmonary 20
   Lateral tunnel 8
   TCPC 17‡
   Kawashima 8
   Unknown 5
*Six with Glenn.
†Three with forward flow, one with concomitant systemic–pulmonary shunt.
‡Five conversions.
CCTGA, congenitally corrected transposition of the great arteries; LV, left ventricle group; RV, right ventricle group; SV, single ventricle group; TCPC, total cavo-pulmonary 
connection
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cerebral abscesses, sepsis and bronchiolitis obliterans). Five 
SV patients had had advanced Fontan associated liver disease 
(FALD) with four unsuitable for combined heart–liver trans-
plant (CHLT). One SV patient had hepatocellular carci-
noma, was actively treated and remains under assessment 
for CHLT.
 ► Too unwell: Seven patients (LV 2, RV 4, SV 1). Two (1 
LV, 1 RV) were pre-VAD era, one RV patient was anatom-
ically unsuitable for VAD (multiple muscular ventricular 
septal defects), one RV patient was stabilised on VAD but 
subsequently died from a complication of a non-cardiac 
procedure, and one RV patient was too unwell for active 
management. One SV patient underwent Fontan revision 
and an Ebstein patient underwent tricuspid valve replace-
ment with extracorporeal membrane oxygenation (ECMO) 
decannulation.
 ► Other reasons: In three cases listing was declined due to 
active smoking, excessive body mass index or medication 
compliance issues.
In addition to these 41 patients, seven who were initially 
unsuitable were bridged to transplant candidacy and listing and 
two underwent dual organ transplant (see below).
Conventional surgery
Conventional surgery or intervention (without VAD) was 
offered to 18/196 patients (9%); in 11 as the preferred option, 
while seven were unsuitable for transplant. Two patients were 
subsequently listed for OHT: one underwent successful OHT 13 
months following aortic valve replacement; the other died on 
the waiting list 12 months after Fontan conversion and desen-
sitisation. At study closure, three patients were awaiting Fontan 
revision, one declined surgery and another died while consid-
ering it (see online supplementary table).
Too well
Thirty-six of 196 (18%) patients (LV 13, RV 10, SV 13) were 
considered too well for OHT and conventional surgery or inter-
vention was not indicated. Two later died: one with repaired 
tetralogy of Fallot and right heart failure 12 years after declining 
reassessment; and the other 18 months after assessment with 
worsening Fontan failure. An additional 14 patients were initially 
considered too well for transplant and subsequently listed 
(median 23.2 months from first assessment, IQR 14.5–94.0). No 
patient moved from the too well group to the unsuitable group.
Other
One Fontan patient with significant FALD underwent CHLT.17 
One patient with Shone complex (TPG did not fall with 
VAD) underwent heart–lung transplant. Four patients had not 
completed the assessment process at study closure. Fourteen 
patients were regarded suitable for OHT but declined listing 
(four were temporarily listed).
listed for OhT
Eighty-nine of 196 patients (45%) were listed for OHT, 52 
urgently. There were no differences in rates of listing or trans-
plantation between diagnostic groups. Seven of 89 (9%) had 
been bridged to candidacy with VAD: six RV patients whose 
pulmonary vascular resistance fell and one following conven-
tional surgery. One underwent conventional surgery as the initial 
treatment of choice but was listed after deteriorating.
Table 2 Comorbidities at assessment for heart transplantation
All lV rV sV
P valuesn=196 n=53 n=57 n=86
Previous sternotomies 1 (0–5) 2 (1–5) 1 (0–4) 2 (0–5) <0.001
Transpulmonary gradient (mm Hg) 6 (4–11) 6 (4–10) 12 (6–17) 5 (4–7) <0.001
PCWP/ventricular EDP (mm Hg) 13 (10–24) 18 (10–26) 23 (12–30) 12 (9–14) <0.001
MPAP (mm Hg) 20 (15–35) 24 (15–38) 37 (20–45) 17 (13–21) <0.001
Creatinine (µmol/L) 98 (82–120) 93 (79–129) 100 (88–119) 94 (79–118) 0.179
Renal replacement therapy 2 1 0 1
Diabetes mellitus 3 0 3 0
Thyroid dysfunction 18 6 3 9
Neurological (prior stroke/cerebral abscess/epilepsy/head injury) 23 6 7 10
Chromosomal abnormality 1 1 0 0
Liver disease (viral hepatitis) 19 2 2 15
Protein losing enteropathy 7 0 0 7
EDP, end diastolic pressure; LV,  left ventricle group; MPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; RV, right ventricle group; SV, single 
ventricle group.  
figure 1 Trends in assessments and transplants over time. Increased 
number of assessments when comparing each 4 year period with 
growth in both the total number of single ventricle patients assessed 
and the proportion of single ventricle patients assessed. The total 
number of transplants has remained fixed when comparing the two 
most recent periods. LV, left ventricle group; RV, right ventricle group; SV, 
single ventricle group.
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Ventricular assist devices
VAD (with or without concomitant surgery) was used in 17 
patients (Heartware (Medtronic, Framingham, MA, USA: 
RV 11, LV 2), Berlin Heart EXCOR (Berlin Heart GmbH, Berlin, 
Germany: RV 1, LV 1, SV 1), SynCardia Total Artificial Heart 
(SynCardia Systems Inc, Tucson, AZ, USA: RV 1)). Outcomes 
of some of the RV cohort have previously been reported.16 Ten 
of 17 (59%) patients were subsequently listed, five were trans-
planted, two died on the waiting list and three remained on the 
list at study close. Of the seven who did not become eligible 
for OHT, four died, one did not achieve a fall in TPG after 18 
months and underwent heart–lung transplant, and two remained 
on support at study close.
survival following assessment
Overall survival was 84.2±2.6% at 1 year, 69.7±3.6% at 5 years, 
and 68.5±3.8% at 10 years. Survival from assessment was not 
significantly influenced by diagnostic group (figure 2, table 4). 
Survival following assessment varied according to decision. 
Those deemed unsuitable for OHT were 11 times more likely to 
die than those who were considered too well for OHT (figure 3, 
table 4).
OuTCOMe And surViVAl fOllOwing lisTing
Nine of 89 (10%) (2 LV, 2 RV, 5 SV) patients listed for transplant 
died on the waiting list (five on the urgent list). Median time from 
listing to death was 24 days (range 2–885 days) while median 
time from listing to transplant was 104 days (range 5–1284) and 
from urgent listing to transplant was 33 days (range 1–507). 
Sixty-seven of 89 (75.2%) were transplanted. Thirteen were 
still waiting at study close. Overall survival following listing was 
80.6±4.2% at 1 year, 70.6±5.2% at 5 years, and 70.6±5.2% at 
10 years. There was no significant difference in survival between 
diagnostic groups (figure 4, figure 5).
surViVAl fOllOwing TrAnsPlAnT
Overall survival following transplant was 85.0±4.4% at 30 days, 
80.4±4.9% at 1 year, 75.9±5.6% at 5 years, and 75.9±5.6% 
at 10 years. There was no difference between diagnostic 
groups (figure 6).
disCussiOn
The growing ACHD population with heart failure has resulted 
in rising numbers being referred for OHT assessment. Further 
increases are expected, particularly in the single ventricle popu-
lation who already account for more than half the assessments 
but <5% of congenital heart disease.1 18–20 Given the hetero-
geneity of the population, different therapeutic approaches to 
address the failing circulation must be considered. We have 
defined three sub-groups by morphological characteristics (LV, 
RV, SV) who, in our experience, can also be grouped by their 
management strategies.
In the LV group, sub-pulmonary right ventricular func-
tion is often the dominant clinical problem limiting conven-
tional medical strategies and use of VADs.6 7 21 The RV group, 
mainly composed of those with atrial switch procedures, 
Table 3 Outcomes following assessment for heart transplantation
All patients lV rV sV
P valuesn=196 n=53 n=57 n=86
Too high risk 41 (21%) 13 (25%) 13 (23%) 15 (17%) NS
Too well 36 (18%) 13 (25%) 10 (18%) 13 (15%) NS
MCS 17 (9%) 3 (6%)* 13 (23%)* 1 (1%)* <0.05
Conventional surgery or 
intervention
13 (7%) 7 (13%) 1 (2%) 5 (6%) NS
Listed 89 (45%) 20 (38%) 27 (47%) 42 (49%) NS
Urgently listed 52 (27%) 9 (17%) 15 (26%) 28 (33%) NS
Assessment to list (months) 3.5
(IQR 0.5–10.6, range 0–92.7)
1.3
(IQR 0.1–6.9, range 0–38.3)
2.3
(IQR 0.2–7.2, range 0–92.7)
4.7
(IQR 1.9–11.6, range 0–47.28)
0.058
Transplanted 67 (34%) 16 (30%) 18 (32%) 33 (38%) NS
NS, not significant on column proportion analysis at p<0.05 level.
*Significant difference between indicated columns on column proportion analysis at p<0.05 level.
Urgently listed patients shown as a proportion of the total number within the group.
LV , left ventricle group; MCS, mechanical circulatory support; RV, right ventricle group; SV, single ventricle group. 
Table 4 Factors associated with survival in patients following assessment for orthotopic heart transplantation in Cox model
Variables hr
95% Ci
P valuelower upper
Age 1.003 0.980 1.026 0.809
Male 0.961 0.552 1.672 0.887
Ventricular morphology
  Left ventricle Reference category
  Right ventricle 0.643 0.307 1.347 0.242
  Single ventricle 1.045 0.567 1.929 0.887
Listing decision
  Too good Reference category
  Listed 3.792 1.138 12.638 0.030
  Unsuitable 11.199 3.296 38.048 <0.001
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present challenges from baffle obstruction, persistent shunts 
and higher TPGs—presumably due to chronically elevated EDP 
and, perhaps, a latent effect of the left to right shunt in early 
childhood. Conventional medical therapy is ineffective in RV 
patients, but they do comparatively well in terms of survival 
at all stages following assessment.6–8 This is partly due to the 
successful reduction in TPG with VAD and bridge to OHT and 
candidacy.16 VAD should be incorporated into national heart 
failure strategies for this group, with patients and their physicians 
educated accordingly. The SV group has significant comorbidity 
with limited options for medical therapy or VAD.6 7 22 23 Optimal 
timing for listing and transplanting these patients is therefore 
key to improving outcomes. Despite comorbidity, survival from 
all time points was comparable with other diagnoses, reflecting 
expertise gained over recent years in assessing and supporting 
this complex group.
Twenty per cent of ACHD patients referred for transplant 
were unsuitable and prognosis was poor. Elevation in the TPG 
and co-morbidity were key factors. Although calculation of 
pulmonary flow and resistance can be performed in ACHD 
patients, flow is often difficult to calculate reliably. We therefore 
tend to use TPG in the majority when deciding on the degree of 
pulmonary vascular disease and its impact on transplant eligi-
bility. Both can be used in the context of transplant assessment.24 
Of those with high TPG, three had left ventricular outflow 
obstruction due to patient–prosthesis miss-match following 
aortic valve replacement as children, leading to irreversible 
pulmonary vascular disease. Close, expert follow-up of ACHD 
patients is essential to ensure early surgical intervention where 
appropriate and avoid such complications. RV patients were 
most frequently found to be unsuitable due to high TPG. Some 
of those turned down were early in our series predating our use 
of VAD, which we have subsequently shown to be effective in 
reducing TPG and perhaps should even be considered for desti-
nation treatment in selected cases.16 Extra cardiac comorbidity 
is particularly pertinent to the Fontan population, with FALD 
(and associated renal dysfunction) being the primary reason 
figure 2 Death-free survival at long term follow-up of 196 patients 
assessed for orthotopic heart transplant (OHT) following assessment 
according to the decision made by the multidisciplinary team.
figure 3 Death-free survival at long term follow-up of 196 patients 
assessed for orthotopic heart transplant following assessment by 
diagnostic group. LV, left ventricle; RV, right ventricle; SV, single ventricle.
figure 4 Death-free survival at long term follow-up of 89 patients 
listed for orthotopic heart transplant following listing by diagnostic 
group. LV, left ventricle; RV, right ventricle; SV, single ventricle.
figure 5 Competing interest curve following listing for transplant. 
All patients start on the curve as listed with the timing of possible 
outcomes transplant or death on the waiting list shown by the other 
curves. No patients were removed from the list for clinical deterioration.
 o
n
 9 July 2019 by guest. Protected by copyright.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2019-314711 on 5 July 2019. Downloaded from 
6 crossland Ds, et al. Heart 2019;0:1–7. doi:10.1136/heartjnl-2019-314711
Congenital heart disease
for turning these patients down for isolated OHT. The point at 
which liver disease precludes OHT and the role of CHLT remain 
ongoing areas for investigation.23 Our Fontan liver surveillance 
programme has evolved over the study period. At present, those 
with cirrhosis but normal synthetic function, normal hepatic 
venous anatomy, good liver volume and no significant portal 
hypertension or hepatocellular carcinoma are considered for 
heart-only transplantation.
Death on the transplant waiting list is a well-recognised 
problem.11–13 Earlier listing and transplantation before major 
comorbidities develop, particularly in those unsuitable for VAD, 
may address this. The disadvantages ACHD patients face on the 
waiting list are well described and changes in UK listing criteria 
and proposed changes in the USA may address this.11–13 15 25 Our 
experience with Fontan patients deteriorating on the list and 
arriving for transplant in a worse clinical condition has led us 
to keep many patients waiting in hospital for daily review and 
proactive management (eg, milrinone infusion) to ensure they 
are optimised when an organ becomes available. The limitation 
of any strategy with transplant at its centre will always be donor 
supply and in our cohort, despite increasing numbers being 
assessed and listed and a small increase in OHTs, the propor-
tion of those transplanted fell. This is reflected in the UK OHT 
numbers which have remained fixed since 2013 despite a rise 
in those patients listed and the growth in the failing UK ACHD 
population.26 27 Two patients in our cohort received dual organ 
transplantation. Limited donor availability is even more perti-
nent to these patients and this is unlikely to be a realistic solution 
for very many ACHD patients.28
Although prognostic biomarkers are being sought for this 
heterogeneous population, robust clinically useful markers to 
guide decision making, particularly as patients approach trans-
plant, are still to be established.29 OHT is an emotive subject, 
and the ability to conduct clinical trials to determine its effective-
ness compared with other strategies is fraught with significant 
ethical and methodological barriers. Mortality as the sole and 
preferred marker of outcome in ACHD transplantation should 
also be questioned. Survival does not consistently equate to 
benefit and patient reported outcome measures should also be 
considered highly relevant in this complex situation.
limitations
This is a single centre experience reporting an MDT decision; 
other units will have different working practices. The level of 
risk that transplant centres are able to tolerate is multifactorial 
and influenced by experience with ACHD patients, overall trans-
plant outcomes and the referral population. Patients have been 
grouped according to perceived clinical commonalities based 
on underlying diagnosis. They remain a heterogeneous group 
with various mechanisms of heart failure and indications for 
transplant. Analysing data by decision at a specific time point is 
complicated and limited as decisions and candidacy change along 
the patient pathway. Regional variation in patient populations 
and referral practices also influence the data presented. In partic-
ular a unit’s decision to carry out high risk conventional surgery 
in place of transplant assessment referral will vary widely. Our 
experience with high risk conventional surgery with mechanical 
support used as back up, an alternative treatment or bridge to 
candidacy, has evolved during the study period and is always 
considered by the MDT. The medium and long term outcomes 
of these alternate strategies are not yet established.
COnClusiOns
The ACHD population referred for OHT assessment will grow 
dramatically over the next few decades. OHT is a component 
of a multifaceted advanced heart failure strategy and should 
be provided by an MDT with expertise in all adjunctive areas 
to identify and manage the anatomical and physiological chal-
lenges. Recognition of the different sub-groups of ACHD heart 
failure patients should lead the medical community to develop 
figure 6 Death-free survival at long term follow-up of 67 patients 
following orthotopic heart transplant by diagnostic group. LV, left 
ventricle; RV, right ventricle; SV, single ventricle.
key questions
what is already known on this subject?
 ► Adults with moderate and complex congenital heart 
disease (ACHD) have higher mortality than the general 
population, with most deaths due to cardiovascular causes, 
particularly heart failure.
 ► Cardiac transplant for ACHD has a relatively high early 
mortality; late outcome (beyond 8 years) is better than 
cardiac transplant for all other causes.
what this study adds
 ► The number of ACHD patients referred for cardiac transplant 
assessment in the UK has quadrupled over 16 years. One 
third undergo transplant.
 ► Survival from assessment is 85% at 1 year and 70% at 5 
years. Underlying congenital diagnosis has no influence on 
subsequent mortality or chance of transplantation. Those 
considered unsuitable or too high risk have worse outcomes 
(survival 63% at 1 year, 44% at 5 years) than those who 
are listed (survival 88% at 1 year, 70% at 5 years) or those 
considered too well (survival 100% at 1 year, 97% at 5 years).
how this might impact on clinical practice
 ► ACHD heart failure patients should be referred early for 
transplant assessment to ensure all alternative options are 
considered. Rigorous follow-up of patients considered too 
well is required to ensure that transplant candidacy is not lost 
due to the development of comorbidity.
 ► Although effective, cardiac transplant is only available to a 
few ACHD patients and counselling of patients at all stages 
should reflect this.
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condition-specific management strategies that include appro-
priate education and support for patients and carers.
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